US EditionPublished • loading... • Updated
FTC warns PBM practices are driving higher drug costs and employers start to push back
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FTC warns PBM practices are driving higher drug costs and employers start to push back
TAMARAC, Fla. – US-Rx Care, the nation's first fiduciary pharmacy risk manager and an industry leader since 2007, is issuing an urgent strategic call-out to employers: the Pharmacy Benefit Manager (PBM) industry has reached a point of no return. After years of hidden incentives, conflicts of interest, and complex revenue models, mounting federal audits, fiduciary litigation, and expanding state regulations are dismantling the industry's long-sta…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
